Benefit of Wearing an Activity Tracker in Sarcoidosis

Drent, Marjolein; Elfferich, Marjon; Breedveld, Ellen; Vries, Jolanda De; Strookappe, Bert

doi:10.3390/jpm10030097

Cited by 17 publications

(8 citation statements)

References 39 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, three-quarters of HCPs would like to monitor physical activity levels, which is done infrequently in current practice. Until now, few studies have evaluated the use of physical activity trackers in ILD (11)(12)(13). Physical activity trackers may be useful to monitor and predict disease deterioration over time, encourage patients to exercise, and enable tele-rehabilitation (11)(12)(13).…”

mentioning

confidence: 99%

Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era

Nakshbandi¹,

Moor²,

Johannson

et al. 2021

ERJ Open Res

View full text Add to dashboard Cite

mentioning

confidence: 99%

Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era

Nakshbandi¹,

Moor²,

Johannson

et al. 2021

ERJ Open Res

View full text Add to dashboard Cite

“…These two variables were investigated before and have shown promising results. 41 We believe that telehealth may potentially provide a valuable way of supporting both physiological and psychological needs of patients with ILD.…”

Section: Discussionmentioning

confidence: 99%

Telehealth for patients with interstitial lung diseases (ILD): results of an international survey of clinicians

Althobiani

Alqahtani²,

Hurst

et al. 2021

BMJ Open Resp Res

View full text Add to dashboard Cite

IntroductionClinicians and policymakers are promoting widespread use of home technology including spirometry to detect disease progression for patients with interstitial lung disease (ILD); the COVID-19 pandemic has accelerated this. Data collating clinicians’ views on the potential utility of telehealth in ILD are limited.AimThis survey investigated clinicians’ opinions about contemporary methods and practices used to monitor disease progression in patients with ILD using telehealth.MethodsClinicians were invited to participate in a cross-sectional survey (SurveyMonkey) of 13 questions designed by an expert panel. Telehealth was defined as home monitoring of symptoms and physiological parameters with regular automatic transmission of data from the patient’s home to the clinician. Data are presented as percentages of respondents.ResultsA total of 207 clinicians from 23 countries participated in the survey. A minority (81, 39%) reported using telehealth. 50% (n=41) of these respondents completed a further question about the effectiveness of telehealth. A majority of respondents (32, 70%) rated it to be quite or more effective than face-to-face visit. There were a greater number of respondents using telehealth from Europe (94, 45%) than Asia (51, 25%) and America (24%). Clinicians reported the most useful telehealth monitoring technologies as smartphone apps (59%) and wearable sensors (30%). Telehealth was most frequently used for monitoring disease progression (70%), quality of life (63%), medication use (63%) and reducing the need for in-person visits (63%). Clinicians most often monitored symptoms (93%), oxygen saturation (74%) and physical activity (72%). The equipment perceived to be most effective were spirometers (43%) and pulse oximeters (33%). The primary barriers to clinicians’ participation in telehealth were organisational structure (80%), technical challenges (63%) and lack of time and/or workload (63%). Clinicians considered patients’ barriers to participation might include lack of awareness (76%), lack of knowledge using smartphones (60%) and lack of confidence in telehealth (56%).ConclusionThe ILD clinicians completing this survey who used telehealth to monitor patients (n=81) supported its’ clinical utility. Our findings emphasise the need for robust research in telehealth as a mode for the delivery of cost-effective healthcare services in ILD and highlight the need to assess patients’ perspectives to improve telehealth utility in patients with ILD.

show abstract

“…Consumer-level activity trackers (e.g., Fitbit, San Francisco, CA, United States) can record multiple parameters including step counts, heart rate, heart rate variability, SpO2, and skin temperature. Data from a small study in sarcoidosis reported an improvement in exercise performance in patients wearing an activity tracker compared to controls ( 33 ). Perceived positive effects may drive many patients to self-initiate activity monitoring using wearables.…”

Section: Current and Future Directionsmentioning

confidence: 99%

Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases

Stanel

Rivera-Ortega²

2023

Front. Med.

View full text Add to dashboard Cite

Progressive fibrosing interstitial lung diseases (PF-ILDs) represent a group of conditions of both known and unknown origin which continue to worsen despite standard treatments, leading to respiratory failure and early mortality. Given the potential to slow down progression by initiating antifibrotic therapies where appropriate, there is ample opportunity to implement innovative strategies for early diagnosis and monitoring with the goal of improving clinical outcomes. Early diagnosis can be facilitated by standardizing ILD multidisciplinary team (MDT) discussions, implementing machine learning algorithms for chest computed-tomography quantitative analysis and novel magnetic-resonance imaging techniques, as well as measuring blood biomarker signatures and genetic testing for telomere length and identification of deleterious mutations in telomere-related genes and other single-nucleotide polymorphisms (SNPs) linked to pulmonary fibrosis such as rs35705950 in the MUC5B promoter region. Assessing disease progression in the post COVID-19 era also led to a number of advances in home monitoring using digitally-enabled home spirometers, pulse oximeters and other wearable devices. While validation for many of these innovations is still in progress, significant changes to current clinical practice for PF-ILDs can be expected in the near future.

show abstract

Benefit of Wearing an Activity Tracker in Sarcoidosis

Cited by 17 publications

References 39 publications

Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era

Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era

Telehealth for patients with interstitial lung diseases (ILD): results of an international survey of clinicians

Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases

Contact Info

Product

Resources

About